Overview / Abstract: |
B-cell non-Hodgkin lymphoma management has advanced significantly in recent years, and patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have been beneficiaries of these advances. However, studies have shown that as many as 40% of patients with CLL/SLL undergoing treatment with novel agents discontinue therapy—the majority of which do so because of adverse events (AEs)—and data suggest that the management of AEs is not consistent with recommendations. Moreover, despite advances in treatment, many patients will relapse, and subsequent treatment decisions are challenging. Real-world and prospective data regarding the impact of treatment sequence on patient outcomes are just emerging, and there is no guidance on sequencing therapies for patients who discontinue first-line therapy due to toxicity or progression. Developed to help hematologist-oncologists, medical oncologists, and other health care providers (HCPs) keep pace with recommended AE management strategies and emerging data for treatment sequencing, this symposium will feature evidence-based presentations interspersed with real-world patient cases designed to provide learners with expert faculty insights and analysis of the clinical implications of new and emerging data for minimizing treatment-emergent AEs and managing treatment sequencing decisions in patients with CLL/SLL. |
Expiration |
Jan 31, 2023 |
Discipline(s) |
Nurse Practitioner , Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences, the Lymphoma Research Foundation, and RedMedEd. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team. Physicians: Rutgers Biomedical and Health Sciences designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Advanced practice nurses, nurses, and physician assistants may participate in this educational activity and earn a letter of attendance as American Academy of Nurse Practitioners (AANP), American Nurses Credentialing Center (ANCC), and American Academy of Physician Assistants (AAPA) accept AMA PRA Category 1 Credit(s)™ through their reciprocity agreements. |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Lindsey E. Roeker, MD—Program Chair Joanna M. Rhodes, MD, MSCE Chaitra S. Ujjani, MD Tarun Wasil, MBBS |
Activity Specialities / Related Topics |
Oncology / Cancer / Radiation Therapy, Hematology, Education / Teaching |
Sponsors / Supporters / Grant Providers |
This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and TG Therapeutics, Inc. The joint sponsors also wish to thank CURE and Targeted Oncology for their support. |
Keywords / Search Terms |
RedMedEd, LRF, Lymphoma Research Foundation, Free, CME, CE, hematology, oncology, chronic lymphocytic leukemia, small lymphocytic lymphoma, CLL, SLL, leukemia, lymphoma, sequencing, treatment sequencing |